Rocket One Seeks Shareholder Approval for Reverse Split and Doubling of Authorized Shares to Regain Nasdaq Compliance
RKTO sits 45% above its 52-week low of $0.489 on light trading volume (0.1× avg).
Summary
Rocket One's proxy seeks approval for a reverse stock split (up to 1-for-15) to regain Nasdaq compliance, plus a doubling of authorized shares and a 3.25M share increase to its equity incentive plan.
Key Events · Corporate Governance and Compliance · RKTO
-
Reverse Stock Split Proposed
Board seeks authority for a reverse split between 1-for-2 and 1-for-15, with discretion to implement before December 17, 2028, to regain Nasdaq's $1.00 minimum bid price compliance.
-
Authorized Shares to Double
Proposal 6 would increase authorized common shares from 50 million to 100 million, giving the board flexibility for future financings but creating significant potential dilution.
-
Equity Plan Expansion
Proposal 3 increases shares reserved under the 2022 Omnibus Equity Incentive Plan from 3,091,317 to 6,341,317 — an additional 3.25 million shares for employee and director compensation.
-
Nasdaq Delisting Risk
Company received a delisting notice on August 6, 2026 for failing to maintain a $1.00 minimum bid price; compliance deadline is February 2, 2027, with a possible 180-day extension.
Analysis · RKTO · Life Sciences
Rocket One is asking shareholders to approve a reverse stock split (up to 1-for-15) and a doubling of authorized shares to 100 million. The reverse split is the company's primary tool to lift its stock price back above Nasdaq's $1.00 minimum bid requirement after receiving a delisting notice in August 2026. The authorized share increase gives the board flexibility for future financings, but it also creates significant potential dilution for existing holders. The equity plan expansion adds 3.25 million shares for compensation, further diluting current shareholders. These proposals are critical because failure to regain compliance by February 2, 2027 could force the stock to the OTC markets, reducing liquidity and investor access.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKTO was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.49 to $2.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.